First Tracks Biotherapeutics, Inc. (TRAX) shareholders
TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026
$47.10−1.60 (-3.29%)
Close on Nov 13, 2026Market cap $1.68BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
92.0%
33M of 36M shares
Institutional holders
149
149 new, 0 sold out
Net institutional buying
33M
In Q2 2026
Insider trades, 12 months
0 buys · 2 sales
Net sold $66.74M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (15.00%) | 6,302,672 | 15.00% | 13G (passive) amendment | Oct 30, 2026 |
| EcoR1 Capital, LLC Joint filing with Oleg Nodelman (9.10%), EcoR1 Capital Fund Qualified, L.P. (8.50%) | 3,174,519 | 9.10% | 13G (passive) | Apr 20, 2026 |
| Chen Yu | 2,895,304 | 8.30% | 13G (passive) | Jun 30, 2026 |
| BlackRock, Inc. | 2,558,473 | 7.20% | 13G (passive) amendment | Sep 30, 2026 |
| Alex Silverstein Joint filing with Sirenia Capital Management LP (7.20%) | 2,495,777 | 7.20% | 13G (passive) | Jun 30, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (5.90%) | 2,054,127 | 5.90% | 13G (passive) | Jun 30, 2026 |
| Michael Cho Joint filing with Affinity Asset Advisors, LLC (5.80%) | 2,032,012 | 5.80% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TRAX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 3,174,519 | 8.88% | $63.87M | New | 3.11% |
| TCG Crossover Management, LLC | 2,895,304 | 8.10% | $58.25M | New | 1.40% |
| FMR LLC | 2,054,127 | 5.75% | $41.33M | New | 0.00% |
| Affinity Asset Advisors, LLC | 2,032,012 | 5.69% | $40.88M | New | 1.85% |
| BlackRock, Inc. | 1,963,541 | 5.50% | $39.51M | New | 0.00% |
| Trails Edge Capital Partners, LP | 1,514,000 | 4.24% | $30.46M | New | 4.84% |
| Vanguard Capital Management LLC | 1,451,909 | 4.06% | $29.21M | New | 0.00% |
| Jupiter Topco LLC | 1,091,464 | 3.05% | $21.96M | New | 0.01% |
| Vestal Point Capital, LP | 1,013,000 | 2.84% | $20.38M | New | 0.48% |
| Woodline Partners LP | 917,176 | 2.57% | $18.45M | New | 0.06% |
| Sanofi | 821,917 | 2.30% | $16.54M | New | 3.10% |
| Morgan Stanley | 781,534 | 2.19% | $15.72M | New | 0.00% |
| 683 Capital Management, LLC | 750,000 | 2.10% | $15.09M | New | 0.74% |
| Adage Capital Partners Gp, L.L.C. | 729,000 | 2.04% | $14.67M | New | 0.02% |
| Balyasny Asset Management L.P. | 714,948 | 2.00% | $14.38M | New | 0.02% |
| Geode Capital Management, LLC | 702,087 | 1.96% | $14.13M | New | 0.00% |
| Bank Of America Corp /De/ | 647,962 | 1.81% | $13.04M | New | 0.00% |
| Stempoint Capital LP | 622,723 | 1.74% | $12.53M | New | 2.16% |
| Palo Alto Investors LP | 603,489 | 1.69% | $12.14M | New | 1.68% |
| Sofinnova Investments, Inc. | 565,199 | 1.58% | $11.37M | New | 0.59% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 149 | 33M | 92.0% | 149 / 0 | 0 / 0 | 33M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of TRAX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,111,470 | 3.11% | $22.36M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 930,353 | 2.60% | $18.72M | 0.17% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 607,976 | 1.70% | $12.23M | 0.01% | Jun 30, 2026 |
| Select Health Care Portfolio | 400,000 | 1.12% | $6.38M | 0.11% | May 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 341,150 | 0.95% | $15.02M | 0.68% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 309,285 | 0.87% | $6.22M | 0.01% | Jun 30, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 290,000 | 0.81% | $12.77M | 0.45% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 255,152 | 0.71% | $11.24M | 0.03% | Jul 31, 2026 |
| Fidelity Advisor Health Care Fund | 200,000 | 0.56% | $8.81M | 0.28% | Jul 31, 2026 |
| Victory Science & Technology Fund | 187,893 | 0.53% | $8.27M | 0.55% | Jul 31, 2026 |
| Vanguard Strategic Equity Fund | 153,153 | 0.43% | $3.08M | 0.03% | Jun 30, 2026 |
| Fidelity Series Small Cap Core Fund | 152,800 | 0.43% | $6.73M | 0.43% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 150,721 | 0.42% | $3.03M | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 101,699 | 0.28% | $1.62M | 0.00% | May 31, 2026 |
| Vanguard Explorer Fund | 98,262 | 0.28% | $4.33M | 0.02% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Daniel Faga | President, CEO, Director | 496,684 | 1.39% | Nov 3, 2026 |
| Paul F. Lizzul | Chief Medical Officer | 42,669 | 0.12% | Nov 3, 2026 |
| Ajim Tamboli | Chief Financial Officer | – | – | Nov 3, 2026 |
| Benjamin Stone | Chief Business Officer | 17,262 | 0.05% | Nov 3, 2026 |
| John A. Orwin | Director | 17,995 | 0.05% | Sep 17, 2026 |
| J. Anthony Ware | Director | 15,660 | 0.04% | Sep 4, 2026 |
| Rita Jain | Director | 19,194 | 0.05% | Jun 17, 2026 |
| John P. Schmid | Director | 37,652 | 0.11% | Jun 17, 2026 |
| Dennis M. Fenton | Director | 10,995 | 0.03% | Jun 17, 2026 |
| Magda Marquet | Director | 15,960 | 0.04% | Jun 17, 2026 |
| EcoR1 Capital, LLC | 10% owner | 7,880,094 | 22.05% | Apr 22, 2026 |
| Anaptysbio, Inc | 10% owner | 0 | – | Apr 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John A. Orwin Director | Sep 15, 2026 | Option exercise | +1,300 | – | – | 17,995 |
| J. Anthony Ware Director | Sep 2, 2026 | Sale | −39,265 | $44.78 | $1.76M | 15,660 |
| J. Anthony Ware Director | Sep 2, 2026 | Option exercise | +39,265 | $5.74 | $225.38K | 54,925 |
| John P. Schmid Director | Jun 15, 2026 | Option exercise | +6,030 | – | – | 37,652 |
| J. Anthony Ware Director | Jun 15, 2026 | Option exercise | +6,030 | – | – | 15,660 |
| Magda Marquet Director | Jun 15, 2026 | Option exercise | +6,030 | – | – | 15,960 |
| Rita Jain Director | Jun 15, 2026 | Option exercise | +7,330 | – | – | 19,194 |
| John A. Orwin Director | Jun 15, 2026 | Option exercise | +6,030 | – | – | 16,695 |
| Dennis M. Fenton Director | Jun 15, 2026 | Option exercise | +6,030 | – | – | 10,995 |
| EcoR1 Capital, LLC 10% owner | Apr 20, 2026 | Sale | +4,705,575 | $13.81 | $64.98M | 3,174,519 |
| Anaptysbio, Inc 10% owner | Apr 20, 2026 | Other | −100 | – | – | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
14.42%
5M shares short
Days to cover
6.5
At 1M shares a day
Change since last report
-27.3%
From 7M shares
Short volume, 20 days
46.1%
Of volume reported to FINRA
Shares sold short, last 7 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of First Tracks Biotherapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 71,189 shares on Oct 13, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| J. Anthony Ware Director | Sep 2, 2026 | 39,265 | $1.76M | Sep 2, 2026 | Stock Option Exercise |
See a number that looks wrong?